As previously discussed, an improved understanding of the role of the RANKL/RANK pathway in cancer biology paved the way for the study of BTAs as a strategy to modify the course of primary cancers and possibly inhibit their metastatic spread, representing a promising opportunity for drug repurposing [91]. The gene discussed is TNFRSF11A; the disease is cancer.